Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351). uri icon

authors

  • Salhotra, Amandeep
  • Budde, Elizabeth
  • Khaled, Samer
  • Dadwal, Sanjeet
  • Snyder, David S
  • Andrew Artz, MD, MS
  • Forman, Stephen
  • Nakamura, Ryotaro
  • Stein, Anthony
  • Marcucci, Guido
  • Aldoss, Ibrahim
  • Aribi, Ahmed
  • Pullarkat, Vinod
  • Ngo, Dat
  • Zhang, Jianying
  • Sandhu, Karamjeet
  • Al-Malki, Monzr
  • Ali, Haris
  • Koller, Paul
  • Arslan, Shukaib

publication date

  • January 1, 2021